glp-1

GLP-1 Weight Loss: Men vs Women—What the Research Really Shows

Explore the latest research on GLP-1 weight loss: men vs women. Learn about differences, side effects, and clinical implications for Ozempic, Wegovy, and more.

Trimm App Support

Trimm App Support

— 14 min read
GLP-1 Weight Loss: Men vs Women—What the Research Really Shows

Estimated reading time: 14 min

Key Takeaways

  • Some studies suggest women may lose more weight than men on GLP-1 weight-loss medications, though both sexes can benefit significantly.
  • The size of the sex difference appears modest but has been observed across semaglutide, liraglutide, dulaglutide, and exenatide in several studies.
  • Biological factors, including hormones and appetite signaling, may contribute to these differences, but the exact mechanisms aren’t fully understood.
  • Side effects—especially gastrointestinal issues—may be more common in women, which can influence tolerability.
  • Personalized tracking and open conversations with your provider are key to maximizing results, regardless of sex.

Table of Contents

Section 1: Overview—GLP-1 Weight Loss for Men vs Women

GLP-1 Medications and Who Uses Them

GLP-1 receptor agonists—such as Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and others—have transformed the landscape of weight management. Originally developed for type 2 diabetes, they've gained FDA approval for obesity treatment due to their effects on appetite and weight loss.

Millions of men and women worldwide now use these medications. In the US alone, prescriptions for GLP-1s have increased in the past few years. People from all walks of life—including those with and without diabetes—are turning to these medications for weight management, often after years of struggling with other approaches.

However, as real-world and clinical trial data accumulate, a pattern has been observed in some studies: women may lose more weight than men when using GLP-1 drugs, even after accounting for differences in starting weight. This trend has been reported in clinical trials and some large health system databases and insurance claims analyses, suggesting it may be a real and persistent phenomenon rather than a statistical fluke, though individual results can vary.

Why Is This “Men vs Women” Question Important?

Understanding GLP-1 weight loss: men vs women isn’t just academic. It shapes expectations, helps guide conversations between patients and providers, and may eventually inform personalized medicine approaches. For anyone on a GLP-1 journey, knowing what’s typical—by sex—can help track progress with the right lens. It also helps prevent frustration or discouragement if your progress differs from that of someone of the opposite sex.

For example, if a woman and man both start GLP-1 therapy at the same time and follow similar routines, it is possible the woman will reach certain weight-loss milestones sooner, even if both are making healthy changes. Having a clear understanding of these trends can support your motivation and help you set realistic, body-positive goals for your unique journey.

Where Does the Evidence Come From?

  • Randomized controlled trials—such as the STEP trials for semaglutide and SCALE for liraglutide
  • Meta-analyses—which pool data from many studies across thousands of participants
  • Real-world cohort studies—offering insights from clinics and electronic health records

These sources suggest there may be a measurable difference in weight-loss outcomes between men and women taking GLP-1 drugs. For instance, in the STEP 1 trial, which enrolled over 1,900 adults with obesity, researchers specifically analyzed outcomes by sex. This level of data granularity is increasingly common as the focus on precision medicine grows.

Importantly, even as we acknowledge these differences, both men and women benefit from GLP-1 medications. The results represent averages, and individual experiences may vary substantially depending on factors like starting weight, age, metabolic health, and lifestyle habits.

Section 2: What the Studies Say—Size of the Sex Difference

Key Findings from Clinical Trials

Some large clinical trials have found that women lose a slightly higher percentage of their starting body weight on GLP-1 drugs compared to men. For example, in the STEP 1 trial (semaglutide 2.4mg weekly, n > 1900), women averaged a higher percentage weight loss than men—a difference of a few percentage points.

While the absolute weight loss (in kilograms) can be similar, the percentage is usually higher in women, due to their lower average baseline body weight. For instance, if a woman starts at 90 kg and loses 14 kg, that's about 15.5% of her starting weight. If a man starts at 110 kg and loses 14 kg, that's about 12.7%. This difference in percentage loss can impact how quickly individuals reach clinically meaningful milestones, such as 5%, 10%, or 15% total body weight loss.

Meta-Analyses: Confirming the Pattern

Several pooled analyses have reported this trend across GLP-1 medications. Some meta-analyses have found women lost, on average, 1.5-3% more of their body weight than men. This difference has been reported after adjusting for age and baseline BMI in some studies, suggesting sex itself may be an independent predictor of response.

  • Women: typically 12–17% body weight loss (in some studies)
  • Men: typically 9–14% body weight loss (in some studies)

However, both men and women see improvements in weight, metabolic health, and quality of life compared to placebo. For example, a few percentage points greater weight loss can translate to several additional kilograms over a year, which may have a meaningful impact on health markers like blood pressure, cholesterol, and blood sugar.

These findings have been reported in diverse populations, including people with and without diabetes, and across different ethnic backgrounds, suggesting the sex difference may be broadly relevant, though more research is needed.

Real-World Evidence

Cohort studies echo some of the clinical trial findings. For example, among users of Ozempic in a large electronic health record study, women lost a higher percentage of weight than men after six months. These are averages—individual results can vary widely. Some men achieve higher-than-average weight loss, while some women lose less, highlighting the importance of looking at your own progress rather than comparing too closely to others.

Researchers have also found that the sex difference in weight loss with GLP-1s is not fully explained by differences in medication adherence or healthcare utilization. When men and women take the same doses for the same amount of time, women may still tend to lose more weight overall, though individual variation is significant.

For personalized tracking and to see how your own journey compares, consider an app like Trimm, which lets you visualize your unique progress and milestones. Trimm’s data-driven approach can help you understand where you stand relative to clinical study averages, and can help you celebrate your achievements regardless of your baseline or sex.

Section 3: GLP-1 Medications—Does It Apply to All?

Semaglutide (Ozempic, Wegovy)

The most robust data on the sex difference in weight loss comes from semaglutide, the active ingredient in both Ozempic and Wegovy. Across the STEP trial program, women often outperformed men in percentage weight loss, though both groups had substantial results. STEP 2, which included people with type 2 diabetes, showed a similar trend, with women achieving a higher mean percentage weight loss.

In addition to overall weight loss, more women reached clinically significant weight loss thresholds (such as 5%, 10%, or 15% weight loss) compared to men in some studies. For instance, in STEP 1, a higher percentage of women reached at least 5% weight loss compared to men. These absolute numbers are impressive for both sexes, but illustrate the small, consistent gap reported in some research.

Want to learn how to log your Wegovy or Ozempic injections accurately? Our step-by-step Wegovy logging guide can help you stay on track.

Liraglutide (Saxenda, Victoza)

Similar trends are seen with liraglutide. The SCALE trials showed a higher proportion of women reaching 5% and 10% weight-loss milestones. The absolute gap was smaller than with semaglutide, but still statistically significant in some studies. In the SCALE Obesity and Prediabetes trial, women lost a higher average percentage of their body weight than men at one year—a modest difference.

Liraglutide is often used as a daily injection, and its effects on appetite and satiety mirror those of once-weekly semaglutide, though the total amount of weight loss tends to be a bit less. Still, women’s outcomes tend to be slightly better, on average, than men’s in some studies.

Dulaglutide, Exenatide, and Other GLP-1s

Data on dulaglutide (Trulicity) and exenatide also suggest women may lose slightly more weight, though these drugs are less commonly used primarily for weight loss. The magnitude of the difference is similar—about 1–2% more for women in some analyses. For example, in a pooled analysis of dulaglutide trials, women averaged a greater weight loss than men.

  • The trend appears consistent across the GLP-1 class in available studies.
  • No GLP-1 medication has yet shown men outperforming women in weight loss in published research.

While newer agents like tirzepatide (Mounjaro, Zepbound) are still being studied, early data suggest the pattern may hold for these as well. Preliminary results indicate a similar percentage gap, with women losing a higher percentage of their body weight than men in clinical trials of tirzepatide for obesity.

It’s important to note that, for all these medications, individual factors—like tolerability, adherence, and lifestyle—have a huge impact on results, sometimes outweighing the influence of sex alone.

Section 4: Biological Explanations for the Sex Gap

Hormonal Influences

Researchers suspect that estrogen and other sex hormones may play a role in modulating the effect of GLP-1 medications. Estrogen may enhance GLP-1 receptor sensitivity, amplifying appetite suppression and satiety signals in women. For example, animal studies suggest that female rodents have greater reductions in food intake when given GLP-1 drugs compared to males, and these effects lessen after removal of estrogen.

In humans, the story is complex. Postmenopausal women, who have lower levels of estrogen, sometimes see a smaller sex difference in GLP-1 response, supporting the idea that hormones are involved. However, even after menopause, women often still lose more weight than men, suggesting additional biological or behavioral factors are involved. Hormonal fluctuations across the menstrual cycle may also influence appetite, cravings, and the subjective experience of medication side effects.

Differences in Appetite Regulation

GLP-1 drugs act mainly by reducing appetite through brain signaling. Some evidence suggests that women may have a more robust appetite response to GLP-1 stimulation, possibly due to differences in brain receptors or downstream pathways.

  • Appetite and satiety responses are complex and influenced by genetics, hormones, and environment.
  • Functional brain imaging studies have shown sex differences in brain activation patterns in response to food cues and GLP-1 drugs.
  • Some researchers hypothesize that women might experience a stronger reduction in reward-driven eating or cravings due to GLP-1 signaling.
  • More research is needed to fully untangle these mechanisms.

In addition, some experts believe that social and environmental factors, such as differences in eating patterns, dieting history, and food-related behaviors between men and women, could interact with biological effects to influence outcomes.

Pharmacokinetics and Body Composition

There are also subtle differences in how men and women process medications. Women tend to have a higher percentage of body fat and lower muscle mass, which may influence the distribution and effect of GLP-1 drugs. Body composition can affect how drugs are absorbed, distributed, and metabolized, although the overall impact on GLP-1 efficacy appears to be modest.

Additionally, studies have found small differences in the pharmacokinetics (how the body processes a drug) of GLP-1 medications by sex, but these do not fully explain the observed differences in weight loss. For example, women may have slightly higher blood concentrations of semaglutide after injection, possibly enhancing appetite suppression. However, these differences are generally small and not the sole driver of the sex gap in outcomes.

Section 5: Factors That May Influence Outcomes

Dosing and Titration

GLP-1 medications are typically titrated to the highest tolerated dose, within FDA guidelines. There is no evidence that men require higher doses for equal effect, and dosing decisions should always be made by a healthcare provider based on tolerability and side effects, not sex alone.

Providers may adjust dosing schedules or titration speed based on how you feel—especially if you experience side effects like nausea or vomiting. It’s important to communicate openly about any symptoms, and to avoid changing the dose or stopping medication without your doctor’s guidance.

Baseline BMI, Age, and Diabetes Status

  • Baseline BMI: Some studies suggest the sex difference in percentage weight loss is consistent across BMI categories. For example, people with a starting BMI of 30-35 or over 40 showed similar sex differences as those in the 35-40 range.
  • Age: The difference may be less pronounced in older adults, especially postmenopausal women. This may reflect changes in hormone levels or metabolism with age, as well as differences in physical activity and diet.
  • Diabetes Status: Both men and women with and without type 2 diabetes lose weight, but the relative difference persists in some studies. Interestingly, people without diabetes tend to lose more weight overall with GLP-1s, but the sex gap is still present in both groups. For more on how GLP-1s work for diabetes, see Understanding GLP-1 for Diabetes: Mechanisms, Benefits, and Future Directions.

Other factors—such as lifestyle, diet, and adherence—play major roles in individual outcomes. For example, someone who maintains consistent healthy eating habits and regular activity, regardless of sex, will tend to see better results than someone who struggles with adherence. Social support, stress management, and sleep quality can also have important effects on weight loss and well-being during GLP-1 therapy.

Treatment Duration

The sex difference in weight loss appears within the first several months and may be maintained over longer-term follow-up (up to 2 years in some trials). However, sustained weight loss requires ongoing medication and lifestyle support. If the medication is stopped, most people—regardless of sex—regain some or all of the lost weight over time, highlighting the importance of long-term strategies.

For support with long-term tracking, Trimm offers an all-in-one solution to log doses, weight, side effects, and visualize milestones over time. Tracking regularly can help you and your provider make informed decisions and catch plateaus or side effect patterns early.

Section 6: Side Effects and Tolerability—Men vs Women

Gastrointestinal Side Effects

The most common side effects of GLP-1 medications are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Studies have reported that women experience these side effects more frequently and sometimes more severely than men. For example, in the STEP 1 trial, a higher percentage of women reported nausea compared to men. Rates for vomiting, diarrhea, and abdominal pain follow a similar pattern.

  • Some analyses have found women have a higher risk of moderate-to-severe nausea than men.
  • Women may also be more likely to report subtle symptoms such as feeling "full" or "bloated," which can impact quality of life and adherence.

This may be due to differences in body size, hormonal influences, or gut-brain signaling. Some researchers speculate that women’s digestive tracts may be more sensitive to changes in motility or hormone signaling, though more research is needed to clarify the causes.

Tolerability and Discontinuation Rates

Women are also slightly more likely to discontinue GLP-1 medications due to side effects, though the majority of both sexes tolerate the drugs well after the titration phase. For example, discontinuation rates due to nausea or vomiting are typically somewhat higher in women than in men, but most people are able to continue with support and symptom management.

Tracking side effects and patterns can help you and your provider troubleshoot tolerability. For step-by-step help, see How to Track Side Effects on GLP-1s: A Step-by-Step Guide. Noting when symptoms occur, their severity, and any triggers (such as certain foods or activities) can help you manage side effects more effectively and have more productive conversations with your healthcare provider.

Other Considerations

  • Women may be more likely to report certain side effects, contributing to observed differences. Social and cultural factors can influence how symptoms are perceived and discussed.
  • Serious adverse events are rare and occur at similar rates in both sexes. Pancreatitis, gallbladder disease, and severe allergic reactions are uncommon.
  • People of any sex who experience new or worsening symptoms—including severe abdominal pain, persistent vomiting, or signs of dehydration—should seek medical attention promptly.

As always, report new or worsening symptoms to your healthcare provider, and never adjust medication on your own. Safety and well-being come first, and your doctor can help you weigh the benefits and risks for your unique situation.

Section 7: Clinical Takeaways—What It Means for You

Both Men and Women Benefit Substantially

While some studies suggest women tend to lose a higher percentage of weight, men still experience clinically meaningful weight loss on GLP-1 medications. For most, the difference is not large enough to change treatment recommendations—both sexes can achieve significant results. In fact, even "average" male responses to GLP-1s are often greater than what is seen with older weight-loss medications or lifestyle changes alone.

GLP-1s can help improve metabolic health, reduce the risk of obesity-related complications, and support a better quality of life for everyone, regardless of sex. Benefits can include improved blood sugar, lower blood pressure, less joint pain, and more energy for daily activities. Many people also report improvements in self-confidence and emotional well-being, reflecting the holistic impact of weight management.

Setting Realistic Expectations

  • It’s normal for men to lose slightly less weight than women on average in some studies. This is a modest difference and does not diminish the health benefits men can achieve.
  • Individual results vary widely—genetics, lifestyle, medical history, and medication adherence matter as much as sex.
  • Comparing your progress to population averages can be helpful, but it’s not the whole story. Focus on your own goals, celebrate your achievements, and be gentle with yourself if weight loss is slower than expected.
  • Remember that weight is only one marker of health. Improvements in energy, fitness, mood, and lab results are equally important.

Monitoring and Maximizing Your Progress

Personalized tracking—of weight, doses, side effects, and habits—can help you and your provider spot trends and optimize your plan. Tools like Trimm help you turn data into actionable insights, so you get the most from your GLP-1 journey. For a full guide, see How to Track GLP-1 Progress: A Complete Guide.

Some practical tips for maximizing your results include:

  • Log your medication doses and any side effects consistently, so you and your provider can spot patterns and adjust your plan as needed.
  • Track your weight and non-scale victories (like improved stamina or clothing fit) regularly, but avoid obsessing over daily fluctuations.
  • Prioritize healthy habits—balanced nutrition, physical activity, sleep, and stress management—to support your medication’s effects. Optimal sleep can also play a crucial role in enhancing weight loss outcomes during GLP-1 therapy.
  • Share your progress and challenges with your provider; they can help you troubleshoot plateaus or side effects and keep you on track.
  • Be patient and compassionate with yourself. Weight management is a journey, and long-term success is built on sustainable, supportive habits.

Remember: Only your doctor can advise on starting, stopping, or adjusting GLP-1 medications. Always discuss concerns or side effects with your provider. Medical decisions are deeply personal and should be made collaboratively, with your health and well-being as the top priority.

Conclusion

GLP-1 weight loss medications offer benefits for both men and women, but research suggests women may lose a slightly higher percentage of their starting weight in some studies. This pattern has been reported across semaglutide, liraglutide, dulaglutide, and exenatide, and is likely influenced by a mix of hormonal, biological, and behavioral factors.

Importantly, the difference—while reported in some studies—is modest, and men can still achieve meaningful, health-improving weight loss. Side effect profiles also differ somewhat, with women experiencing more GI symptoms on average. Individual experience will always vary, so tracking your own journey and partnering closely with your provider is key.

Weight loss is not the sole marker of success—improvements in health, well-being, and self-care matter just as much. A body-positive, supportive approach can help you celebrate progress, overcome challenges, and build a sustainable path forward.

For support in logging doses, side effects, and progress, apps like Trimm can provide structure and motivation every step of the way.

FAQ

Q: Do women lose more weight than men on Ozempic or Wegovy?

A: Some clinical trials and real-world data suggest women tend to lose a higher percentage of their starting body weight than men when taking semaglutide (Ozempic, Wegovy). However, both men and women can see significant weight loss compared to placebo. For a comprehensive overview of these medications, results, and safety, see our GLP-1 Weight Loss: The Definitive Guide to Medications, Results, and Safety.

Q: How much more weight do women lose on GLP-1 medications than men?

A: On average, some studies report women lose about 1.5–3% more of their starting body weight than men. For example, women may lose 15% while men lose 12%, though there is wide individual variation and not all studies find the same difference.

Q: Why do GLP-1 drugs work better for women than men?

A: The exact reason isn’t fully understood, but it may relate to differences in hormone levels (like estrogen), appetite signaling, and GLP-1 receptor sensitivity. More research is needed.

Q: Does the men vs women difference happen with semaglutide only or all GLP-1s?

A: The trend has been reported across several GLP-1 drugs, including semaglutide, liraglutide, dulaglutide, and exenatide. Women tend to lose slightly more weight on all these medications in some studies.

Q: Are side effects different for men and women on GLP-1 weight-loss drugs?

A: Yes, women are more likely to experience gastrointestinal side effects like nausea or vomiting in some studies. However, both sexes generally tolerate GLP-1 medications well.

Q: Can men still lose a lot of weight on GLP-1 medications?

A: Absolutely. Men can achieve substantial, health-improving weight loss with GLP-1s, even if the average percentage is a bit lower than women in some studies. Individual results depend on many factors.

Read more